FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2019284100> ?p ?o ?g. }

• W2019284100 endingPage "1011" @default.
• W2019284100 startingPage "1002" @default.
• W2019284100 abstract "In Brief Purpose: The purpose of this study was to compare the injection burden, central macular thickness (CMT), and change in best-corrected visual acuity after injecting 1.25 mg or 2.5 mg bevacizumab as needed in patients with primary macular edema secondary to central retinal vein occlusion. Methods: This is an interventional, retrospective, comparative multicenter study of 86 eyes with macular edema secondary to central retinal vein occlusion that were treated primarily with intravitreal bevacizumab (44 eyes, 1.25 mg; 42 eyes, 2.5 mg). The main outcome measures were the CMT and the change of best-corrected visual acuity at 24 months. Results: All patients completed at least 24 months of follow-up. The mean number of injections per eye were 7.2 for the 1.25-mg dose group and 8.1 for the 2.5-mg dose group (P = 0.4492). At 24 months, in the 1.25-mg dose group, the logarithm of the minimal angle of resolution best-corrected visual acuity improved from baseline 0.35 ± 0.57 units (P < 0.0001) versus 0.27 ± 0.68 units for the 2.5-mg dose group (P < 0.0001). These differences were not statistically significant between both dose groups. In the 1.25-mg dose group, 25 (56.8%) eyes gained ≥3 lines of Early Treatment of Diabetic Retinopathy Study visual acuity and 6 (13.6%) lost ≥3 lines of Early Treatment of Diabetic Retinopathy Study visual acuity. In the 2.5-mg dose group, 24 (57.1 %) eyes improved ≥3 lines of Early Treatment of Diabetic Retinopathy Study visual acuity and 7 (16.7%) lost ≥3 lines of Early Treatment of Diabetic Retinopathy Study visual acuity. The CMT in the 1.25-mg dose group improved from 635 ± 324 μm to 264 ± 160 μm (P < 0.0001) versus 528 ± μm to 293 ± 137 μm in the 2.5-mg dose group (P < 0.0001). There was no statistically significant difference between both dose groups with regard to the CMT reduction. Conclusion: Intravitreal bevacizumab at doses up to 2.5 mg seems to be effective in improving visual acuity and reducing CMT in macular edema secondary to central retinal vein occlusion. There were no statistically significant differences between the two dose groups with regard to the number of injections, CMT, and change in visual acuity. Eyes with macular edema secondary to central retinal vein occlusion that were treated with multiple injections of intravitreal bevacizumab exhibit improved visual acuity and macular thickness during 2 years of follow-up." @default.
• W2019284100 created "2016-06-24" @default.
• W2019284100 creator A5006300302 @default.
• W2019284100 creator A5008720591 @default.
• W2019284100 creator A5011423214 @default.
• W2019284100 creator A5026826216 @default.
• W2019284100 creator A5074412670 @default.
• W2019284100 creator A5075715126 @default.
• W2019284100 creator A5080205917 @default.
• W2019284100 creator A5089531087 @default.
• W2019284100 date "2010-07-01" @default.
• W2019284100 modified "2023-09-27" @default.
• W2019284100 title "COMPARISON OF TWO DOSES OF INTRAVITREAL BEVACIZUMAB AS PRIMARY TREATMENT FOR MACULAR EDEMA SECONDARY TO CENTRAL RETINAL VEIN OCCLUSION" @default.
• W2019284100 cites W1484703211 @default.
• W2019284100 cites W1517718326 @default.
• W2019284100 cites W1522310362 @default.
• W2019284100 cites W1574902248 @default.
• W2019284100 cites W1601975653 @default.
• W2019284100 cites W1963851116 @default.
• W2019284100 cites W1972105764 @default.
• W2019284100 cites W1973704949 @default.
• W2019284100 cites W1974030864 @default.
• W2019284100 cites W1977995451 @default.
• W2019284100 cites W1978037771 @default.
• W2019284100 cites W1983942352 @default.
• W2019284100 cites W1996377899 @default.
• W2019284100 cites W2013671556 @default.
• W2019284100 cites W2020707825 @default.
• W2019284100 cites W2033680298 @default.
• W2019284100 cites W2037623358 @default.
• W2019284100 cites W2041611183 @default.
• W2019284100 cites W2054438872 @default.
• W2019284100 cites W2068100937 @default.
• W2019284100 cites W2068779395 @default.
• W2019284100 cites W2069330755 @default.
• W2019284100 cites W2069739861 @default.
• W2019284100 cites W2071206465 @default.
• W2019284100 cites W2075820248 @default.
• W2019284100 cites W2079095010 @default.
• W2019284100 cites W2080689845 @default.
• W2019284100 cites W2082208163 @default.
• W2019284100 cites W2093446675 @default.
• W2019284100 cites W2099447631 @default.
• W2019284100 cites W2103391490 @default.
• W2019284100 cites W2115060781 @default.
• W2019284100 cites W2126501086 @default.
• W2019284100 cites W2128535483 @default.
• W2019284100 cites W2133950656 @default.
• W2019284100 cites W2141091492 @default.
• W2019284100 cites W2142651474 @default.
• W2019284100 cites W2151081020 @default.
• W2019284100 cites W2152816807 @default.
• W2019284100 cites W2154763327 @default.
• W2019284100 cites W2157769714 @default.
• W2019284100 cites W2169580554 @default.
• W2019284100 cites W2233259956 @default.
• W2019284100 cites W2324588265 @default.
• W2019284100 cites W2915852396 @default.
• W2019284100 cites W3152900 @default.
• W2019284100 cites W4297917733 @default.
• W2019284100 doi "https://doi.org/10.1097/iae.0b013e3181cea68d" @default.
• W2019284100 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/20616679" @default.
• W2019284100 hasPublicationYear "2010" @default.
• W2019284100 type Work @default.
• W2019284100 sameAs 2019284100 @default.
• W2019284100 citedByCount "41" @default.
• W2019284100 countsByYear W20192841002012 @default.
• W2019284100 countsByYear W20192841002013 @default.
• W2019284100 countsByYear W20192841002014 @default.
• W2019284100 countsByYear W20192841002015 @default.
• W2019284100 countsByYear W20192841002016 @default.
• W2019284100 countsByYear W20192841002017 @default.
• W2019284100 countsByYear W20192841002018 @default.
• W2019284100 countsByYear W20192841002020 @default.
• W2019284100 countsByYear W20192841002021 @default.
• W2019284100 countsByYear W20192841002022 @default.
• W2019284100 crossrefType "journal-article" @default.
• W2019284100 hasAuthorship W2019284100A5006300302 @default.
• W2019284100 hasAuthorship W2019284100A5008720591 @default.
• W2019284100 hasAuthorship W2019284100A5011423214 @default.
• W2019284100 hasAuthorship W2019284100A5026826216 @default.
• W2019284100 hasAuthorship W2019284100A5074412670 @default.
• W2019284100 hasAuthorship W2019284100A5075715126 @default.
• W2019284100 hasAuthorship W2019284100A5080205917 @default.
• W2019284100 hasAuthorship W2019284100A5089531087 @default.
• W2019284100 hasConcept C118487528 @default.
• W2019284100 hasConcept C134018914 @default.
• W2019284100 hasConcept C141071460 @default.
• W2019284100 hasConcept C2776268601 @default.
• W2019284100 hasConcept C2776694085 @default.
• W2019284100 hasConcept C2777802072 @default.
• W2019284100 hasConcept C2778257484 @default.
• W2019284100 hasConcept C2778844676 @default.
• W2019284100 hasConcept C2779829184 @default.
• W2019284100 hasConcept C2780347916 @default.
• W2019284100 hasConcept C2780827179 @default.
• W2019284100 hasConcept C2908732032 @default.
• W2019284100 hasConcept C555293320 @default.

• next